RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo
Pancreatic neuroendocrine tumors (pNETs) are difficult-to-treat neoplasms whose incidence is rising. Greater understanding of pNET pathogenesis is needed to identify new biomarkers and targets for improved therapy. RABL6A, a novel oncogenic GTPase, is highly expressed in patient pNETs and required f...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
MDPI AG
2021-06-01
|
| Ráidu: | Biomedicines |
| Fáttát: | |
| Liŋkkat: | https://www.mdpi.com/2227-9059/9/6/633 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
